Case Studies

Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. LIFESCI’s ACTIVITIES LifeSci engaged following a global strategic partnership with Terumo announced in June 2019 Strengthen the equity story and position the Company to secure additional strategic global partnerships Raise visibility…

LifeSci have worked extensively over the years to raise the Company’s visibility amongst investors and strategics, preparing the market for their positive data read out and ultimately leading to a successful acquisition. LIFESCI’s ACTIVITIES Strengthen Amryt’s position as a global leader in rare and orphan diseases through strategic corporate communications following the acquisition of Chiasma…

BACKGROUND Bellus Health is a clinical-stage biopharmaceutical company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of refractory chronic cough. LifeSci Advisors has been engaged to support Bellus Health with investor…

LIFESCI’s ACTIVITIES Aggressive outreach to new investors and sell-side analysts Arranged 80 TTW and IPO roadshow meetings Arranged 13 meetings during the 2022 LifeSci Corporate Access Event Worked with management to strengthen messaging and optimize competitive positioning for MAU868 and other pipeline programs Organized two well-attended KOL events for ‘Ataciept’ and ‘MAU868’. Provided capital markets…

Background PharmaMar is a commercial-stage oncology company headquartered in Spain and listed on the Bolsas y Mercados Españoles exchange. Despite the successful commercial launch of PharmaMar’s product Zepzelca® (lurbinectedin) in 2020 by partner Jazz Pharmaceuticals as a second-line treatment for SCLC, the Zepzelca® story struggled to gain traction with investors and the broader PharmaMar investment…

In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of promising COVID-19, Lyme Disease, and Chikungunya vaccines. LifeSci worked to raise Valneva’s visibility among the investment community and position Valneva for a successful US dual-listing and global equity offering.  …